Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan

Psychiatry and Clinical Neurosciences
Wenyu YeTetsuro Ohmori

Abstract

This study assessed clinical and functional outcomes following a switch from risperidone to olanzapine in a 1-year naturalistic study of schizophrenia patients in Japan. We used data from a large 1-year prospective, multicenter, observational non-interventional study of individuals who were initiated on olanzapine for the treatment of schizophrenia in Japan. Current analyses focused on patients who were switched at study entry from risperidone to olanzapine (n = 258). Repeated measures analysis was employed to assess outcomes on validated measures. At study entry, 45% were inpatients and 55% outpatients. Participants were in their early 40s with mean illness duration of 14 years. Approximately half were male. Most were switched from risperidone to olanzapine due to poor medication efficacy (67.8%) rather than medication intolerability (29.1%). Most patients (67.8%) completed the 1-year study. Patients experienced clinically and statistically significant (P < 0.05) improvements in global symptom severity, positive, negative, depressive, and cognitive symptoms, health-related quality of life, and paid work rates. Most patients (59.2%) demonstrated treatment response to olanzapine and 43.4% experienced symptom remission. Mean weig...Continue Reading

References

Dec 1, 1992·Hospital & Community Psychiatry·S D SoniK Gaskell
May 21, 2003·Acta Psychiatrica Scandinavica. Supplementum·J M HaroUNKNOWN SOHO Study Group
Dec 18, 2003·Psychiatry and Clinical Neurosciences·Mian-Yoon ChongNaotaka Shinfuku
Jan 22, 2005·The Australian and New Zealand Journal of Psychiatry·UNKNOWN Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophren
Aug 2, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Sylvia ParkStephen B Soumerai
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Jun 9, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Hitoshi TakahashiHisashi Higuchi
Nov 18, 2006·Journal of Clinical Psychopharmacology·Josep Maria HaroUNKNOWN SOHO Study Group
Jan 24, 2007·Psychiatry and Clinical Neurosciences·Iwao OshimaYoshimasa Inomata
Sep 19, 2007·Psychiatry and Clinical Neurosciences·Miharu NakanishiNobuo Anzai
Nov 18, 2008·International Review of Psychiatry·Naotaka Shinfuku, Chay-Hoon Tan
Nov 26, 2008·Schizophrenia Research·T Scott StroupUNKNOWN CATIE Investigators
Apr 2, 2009·Psychological Medicine·S LeuchtJ M Davis
Dec 4, 2009·Schizophrenia Bulletin·Robert W BuchananUNKNOWN Schizophrenia Patient Outcomes Research Team (PORT)

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here